Impact of Insulin on Sympathetic Nervous System-mediated Peripheral Vasoconstriction

Healthy Clinical Trial

Official title:

Impact of Insulin on Sympathetic Nervous System-mediated Peripheral Vasoconstriction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05244694
• Other study ID #: 2020286
• Status: Completed
• Phase: Early Phase 1
• Start date: August 6, 2020
• Est. completion date: June 25, 2021

Study information

• Verified date: February 2023
• Source: University of Missouri-Columbia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this project is to determine if hyperinsulinemia attenuates sympathetic nervous system-mediated vasoconstriction in the human leg.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: June 25, 2021
• Est. primary completion date: June 25, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• healthy adult men and women;

• 18-45 years of age;

• BMI 18-30 kg/m2;

• non-pregnant/non-breastfeeding;

• non-nicotine users;

Exclusion Criteria:

• taking any medications known to affect metabolic, respiratory, cardiovascular, and/or autonomic functions

Self-reported history of:

• hepatic, renal, pulmonary, cardiovascular, or neurological disease;

• stroke or neurovascular disease;

• bleeding/clotting disorders;

• sleep apnea or other sleep disorders;

• diabetes;

• smoking;

• history of alcoholism or substance abuse, excessive alcohol consumption;

• hypertension;

• active cancer;

• autoimmune disease;

• immunosuppressant therapy

Related Conditions & MeSH terms

• Healthy
• Insulin Resistance
• Vasoconstriction

Intervention

Drug:
• Insulin
Priming dose then a constant infusion at 40 mU•m-2•min-1

Locations

Country	Name	City	State
United States	University of Missouri	Columbia	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
University of Missouri-Columbia

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Amount of leg blood flow	Measured with Doppler ultrasound (mL/min)	Change from baseline at minute 60
Secondary	Amount of muscle sympathetic nerve activity (MSNA)	MSNA burst incidence (bursts/100 heart beats)	Change from baseline at minute 60
Secondary	Amount of cerebral blood flow	Measured with trans-cranial Doppler ultrasound (cm/s)	Change from baseline at minute 60